Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Invesco Pharmaceuticals ETF
(NY:
PJP
)
107.85
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5
Open
107.85
Bid (Size)
102.83 (100)
Ask (Size)
113.95 (100)
Prev. Close
107.85
Today's Range
107.85 - 107.85
52wk Range
72.25 - 108.40
Shares Outstanding
28,900
Dividend Yield
0.88%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report
↗
December 01, 2025
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.
Via
Stocktwits
Topics
World Trade
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
↗
November 12, 2025
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
Via
Benzinga
Performance
YTD
+29.9%
+29.9%
1 Month
+1.6%
+1.6%
3 Month
+18.3%
+18.3%
6 Month
+35.0%
+35.0%
1 Year
+31.3%
+31.3%
More News
Read More
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
↗
September 29, 2025
Via
Benzinga
Topics
Government
World Trade
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
↗
July 21, 2025
Via
Stocktwits
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
↗
September 08, 2025
Via
Benzinga
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
↗
August 01, 2025
Via
Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
↗
July 16, 2025
Via
Benzinga
Topics
Government
World Trade
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report
↗
July 11, 2025
Via
Stocktwits
Topics
Government
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
↗
July 11, 2025
Via
Benzinga
Topics
Government
World Trade
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
↗
June 20, 2025
Via
Benzinga
FDA Aims To Reduce Drug Application Review Time With New Voucher Program
↗
June 17, 2025
Via
Stocktwits
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
↗
May 19, 2025
Via
Benzinga
Topics
Government
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
↗
May 11, 2025
Via
Benzinga
Topics
Government
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
↗
April 28, 2025
Via
Stocktwits
Topics
Government
Intellectual Property
Lawsuit
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
↗
April 23, 2025
Via
Benzinga
Topics
Government
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
↗
April 11, 2025
Via
Benzinga
Topics
Government
World Trade
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
↗
November 13, 2024
Via
Benzinga
Topics
Government
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
↗
August 19, 2024
Via
Benzinga
Topics
ETFs
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
↗
July 18, 2024
Via
Benzinga
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
↗
June 27, 2024
Via
Benzinga
Topics
Bankruptcy
Lawsuit
A Look At Pharma ETFs Post Q1 Earnings
↗
May 07, 2024
Via
Talk Markets
Topics
ETFs
A Look At Pharma ETFs After Q4 Earnings
↗
February 12, 2024
Via
Talk Markets
Topics
ETFs
Government-granted Patent Monopolies Are Not The Free Market
↗
December 29, 2023
Via
Talk Markets
Topics
Intellectual Property
Time For Gilead Sciences-Heavy ETFs?
↗
September 12, 2023
Via
Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
↗
August 11, 2023
Via
Talk Markets
Topics
ETFs
Frequently Asked Questions
Is Invesco Pharmaceuticals ETF publicly traded?
Yes, Invesco Pharmaceuticals ETF is publicly traded.
What exchange does Invesco Pharmaceuticals ETF trade on?
Invesco Pharmaceuticals ETF trades on the New York Stock Exchange
What is the ticker symbol for Invesco Pharmaceuticals ETF?
The ticker symbol for Invesco Pharmaceuticals ETF is PJP on the New York Stock Exchange
What is the current price of Invesco Pharmaceuticals ETF?
The current price of Invesco Pharmaceuticals ETF is 107.85
When was Invesco Pharmaceuticals ETF last traded?
The last trade of Invesco Pharmaceuticals ETF was at 12/26/25 08:00 PM ET
What is the market capitalization of Invesco Pharmaceuticals ETF?
The market capitalization of Invesco Pharmaceuticals ETF is 3.12M
How many shares of Invesco Pharmaceuticals ETF are outstanding?
Invesco Pharmaceuticals ETF has 3M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.